{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '14.7', 'SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES', '90', '14.8', 'PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF', 'A SITE', '90', '14.8.1', 'By the Sponsor', '90', '14.8.2', 'By the Investigator', '91', '14.9', 'CLINICAL TRIAL RESULTS', '91', '14.10', 'PUBLICATIONS AND COMMUNICATIONS', '91', '15', 'CLINICAL TRIAL PROTOCOL AMENDMENTS', '92', '16', 'BIBLIOGRAPHIC REFERENCES', '93', '17', 'APPENDICES', '96', 'APPENDIX A GENERAL GUIDANCE FOR THE FOLLOW-UP OF LABORATORY', 'ABNORMALITIES BY SANOFI', '97', 'APPENDIX B PROCEDURE FOR COLLECTION, HANDLING, STORAGE, AND SHIPMENT OF', 'SAR407899 SPECIMENS FOR PHARMACOGENETIC SAMPLES', '102', 'APPENDIX C PATIENT REPORTED OUTCOMES', '105', '2.1', 'LIST OF TABLES', 'Table 1 - Summary of sampling/handling procedures for', '58', 'Table 2 - Summary of sampling/handling procedures for', '58', 'Table 3 - Summary of sampling/handling procedures for future use of samples', '58', 'Table 4 - Sampled blood volume', '59', 'Table 5 - Summary of adverse event reporting instructions', '75', '2.2', 'LIST OF FIGURES', 'Figure 1 - Rho kinase pathway', '31', 'Property of the Sanofi Group - strictly confidential', 'Page 27', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '3', 'LIST OF ABBREVIATIONS', 'ACS:', 'acute coronary syndrome', 'AE:', 'adverse event', 'AESI:', 'adverse event of special interest', 'AV:', 'atrioventricular', 'BP:', 'blood pressure', 'CABG:', 'coronary artery bypass grafting', 'CAD:', 'coronary artery disease', 'CCBs:', 'calcium channel blockers', 'CCTA:', 'coronary computed tomography angiography', 'CFR:', 'coronary flow reserve', 'CVR:', 'coronary vascular resistance', 'DBTP:', 'double blind treatment package', 'DMC:', 'data monitoring committee', 'eGFR:', 'estimated glomerular filtration rate', 'eNOS:', 'endothelial nitric oxide synthase', 'FFR:', 'fractional flow reserve', 'FSH:', 'follicle stimulating hormone', 'HRT:', 'hormonal replacement therapy', 'IAG:', 'imaging acquisition guidelines', 'IEC:', 'independent ethics committee', 'iFR:', 'instantaneous wave-free ratio', 'IMP:', 'investigational medicinal product', 'IRB:', 'institutional review board', 'IRT:', 'interactive response technology', 'LAD:', 'left anterior descending', 'LCX:', 'left circumflex', 'LV:', 'left ventricle', 'LVEF:', 'left ventricular ejection fraction', 'MAPK:', 'mitogen-activated protein kinases', 'MBF:', 'myocardial blood flow', 'MI:', 'myocardial infarction', 'mL:', 'milliliter', 'NIMP:', 'non investigational medicinal product', 'OCT2:', 'organic cation transporter-2', 'PCI:', 'percutaneous coronary intervention', 'RCA:', 'right coronary artery', 'SAE:', 'serious adverse event', 'SBP:', 'systolic blood pressure', 'TEAE:', 'treatment-emergent adverse events', 'Property of the Sanofi Group - strictly confidential', 'Page 28', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'TIA:', 'transient ischemic attack', 'TPD:', 'total perfusion deficit', 'Property of the Sanofi Group - strictly confidential', 'Page 29', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}